Launching 2026

GJS Intelligence separates scientific signal from commercial overreach.

The consumer health industry doesn't ignore science — it uses it constantly. Brands deploy evidence to build trust, authority, and premium pricing: legitimate commercial uses that don't require the evidence to actually translate into the product. The gap between what a label implies and what a product delivers is structural, not accidental. GJS Intelligence exists to close it.

Three observations that frame the buyer's exposure:

The evidence serves the marketing. The product serves the margin. The buyer carries the consequence.

Marketing-first markets produce predictable mismatches between scientific evidence and commercial execution. These are not random events. They are the rational outputs of the economic and regulatory structure.

The relevant question is never simply whether the science exists. It is whether this product, test, or claim accurately reflects that science — for the right population, in the right context, at the right standard.

— First-access registration

First access to the inaugural GJS Intelligence Report.

Operators, investors, and practitioners commit capital, reputation, and recommendation based on their assessments of health products. Register and we'll notify you when the inaugural report is available — and when new reports follow.

Inaugural Report The Cellular Ageing Supplement Audit Evidence audit · T1–T5 product classification · Commercial whitespace · Regulatory exposure

Confirmed

You're on the list.

We'll be in touch when the inaugural report is available — and when new reports follow. Registered address:

—